This phase I trial is investigating how safe and tolerable a new targeted therapy (ATG-101) is in people with metastatic or advanced solid cancers, and mature B-cell Non-Hodgkin Lymphoma.
This trial is treating patients with metastatic or advanced solid cancers and mature B-cell Non-Hodgkin Lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A First-in-Human Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Antengene Biologics Limited
This trial has two phases: A Dose Escalation Phase and a Dose Expansion Phase. In the Dose Escalation Phase, ATG-101 will be administered intravenously (via IV) once every 21 days in increasing doses until the recommended phase 2 dose (RP2D) or maximum tolerated dose (MTD) or biologically optimal dose is determined. In the Dose Expansion Phase, ATG-101 will be administered at the dose level determined in the Dose Escalation Phase.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More